Our Research

Discover our recent findings, catch up with news, and review in-depth resources.

Development and Validation of an Immunogenicity Assay for Detection of Anti-AAV Antibodies

CASE STUDY – ANTI-AAV ANTIBODIES. We are experienced with a wide range of different proteins and therapeutics…

Pharmacokinetics (PK) Urine Analysis

Whereas blood is collected for analysis at a discrete time point, urine is collected over periods of time known as collection intervals…

Challenges of Developing an ADA Assay for Bispecific Antibody Therapeutics and ADA Characterization

Bispecifics (Bs) are biopharmaceutical products that bind to two different targets (epitopes). These are mainly two types: IgG-like (antibodies Abs) and non-IgG-like which include Bites (bispecific T-cell engager) and DARTs (Dual-affinity Re-targeting Antibody)…

What Makes a Good LC-MS/MS Bioassay?

Liquid chromatography linked to tandem mass spectrometry (LC–MS/MS, LC-MS) is the “go-to” method for pharmacokinetics and metabolism studies across drug development with recent advances in separation, throughput and methods for analyzing protein biotherapeutics…

Beyond the Abstract: An Interview with Ashley Phillips

In this Bioanalysis Zone podcast episode, our Senior Scientist and Technical Specialist Ashley Phillips discusses his recent publication…

A Step-by-Step Guide to Developing a Robust Assay in Bioanalysis Using LC-MS/MS

LC-MS/MS assay development within Bioanalysis is driven by developing accurate, precise and robust methods within the shortest time frame possible…
Scroll to Top

Resolian Opens Expanded State-of-the-Art Analytical Laboratory in Fordham

June 29, 2023

Resolian, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, has opened its 440m² analytical laboratory in Fordham, Cambridgeshire, UK.

The new analytical lab, which the company announced plans for earlier this year, provides a 30% larger lab to help meet the rising demand for analytical and materials science work.

“We are delighted to have expanded our lab at Fordham by over 30% to meet the growing demand.” said Analytical Sciences Operations Director Ellen Stokvis. “Our new state-of-the-art purpose-built lab further strengthens our analytical and materials science capabilities. Increasing lab space from 330m² to 440m² enables more companies to be able to work with us.

“The new laboratory space has been designed to support better collaboration and improved workflow and traffic flow and alongside our Sandwich site, this investment in the analytical and materials science area of our business means we are set up and ready to support our customers demand now and in the future.”

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.